Patent · US Active

Line leaf inula flower lactone A and methods for preparing and using the same for treating multiple sclerosis

US9278948B2 · kind B2 · utility

1Cited by

0References

4Claims

0Family size

Assignee

SHANXI ZHENDONG PILOT BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD. · CN

Inventors

Weidong Zhang · Shanghai, CN
Lei Shan · Shanghai, CN
Juan Su · Shanghai, CN
Huizi Jin · Shanghai, CN
Huiliang Li · Shanghai, CN
Yunheng Shen · Shanghai, CN
Xike Xu · Shanghai, CN
Runhui Liu · Madison, US

Key dates

Filing date	Dec 18, 2014
Grant date	Mar 8, 2016
Priority date	—
Expiry date	Dec 18, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2236/39
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure ofLine leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.